Hims & Hers shares plunge 12% amid allegations of GLP-1 drug sourcing from ‘shady supplier’

A new report criticized Hims GLP-1 offerings, specifically where the company is getting them from.

Roughly a month after announcing that it would offer GLP-1 injectable weight-loss drugs comparable to the popular drugs Ozempic and Mounjaro, Hims & Hers Health shares are taking a beating after a new report criticized those offerings, saying that they’re being acquired through a “shady supplier.”